Interim-treatment quantitative PET parameters predict progression and death among patients with hodgkin's disease

Radiation Oncology

Volumn 7, Issue 1, 2012, Pages

  Tseng, Diane ^a   Rachakonda, Leelanand P ^a   Su, Zheng ^a   Advani, Ranjana ^a   Horning, Sandra ^a   Hoppe, Richard T ^a   Quon, Andrew ^a   Graves, Edward E ^a   Loo Jr, Billy W ^a   Tran, Phuoc T ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Hodgkin's disease; Metabolic tumor volume; PET; Quantitative PET parameters; Survival

Indexed keywords

BLEOMYCIN; CHLORAMBUCIL; DACARBAZINE; DOXORUBICIN; PREDNISOLONE; PROCARBAZINE; VINBLASTINE; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHILD; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; INTERNATIONAL PROGNOSTIC SCORE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PARAMETERS; POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL; SCHOOL CHILD; TUMOR VOLUME; DISEASE COURSE; MIDDLE AGED; MORTALITY; PROGNOSIS; RETROSPECTIVE STUDY; SCINTISCANNING;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; DISEASE PROGRESSION; FEMALE; FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84855878177     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-7-5     Document Type: Article

References (21)

1. Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, Green MR, Gottlieb A, Peterson BA. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992, 327:1478-1484. 10.1056/NEJM199211193272102, 1383821.
2. Gallamini A, Rigacci L, Merli F, Nassi L, Bosi A, Capodanno I, Luminari S, Vitolo U, Sancetta R, Iannitto E, Trentin L, Stelitano C, Tavera S, Biggi A, Castagnoli A, Versari A, Gregianin M, Pelosi E, Torchio P, Levis A. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica 2006, 91:475-481.
3. Hutchings M, Loft A, Hansen M, Pedersen LM, Buhl T, Jurlander J, Buus S, Keiding S, D'Amore F, Boesen AM, Berthelsen AK, Specht L. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006, 107:52-59. 10.1182/blood-2005-06-2252, 16150944.
4. Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, Patti C, Loft A, Di Raimondo F, D'Amore F, Biggi A, Vitolo U, Stelitano C, Sancetta R, Trentin L, Luminari S, Iannitto E, Viviani S, Pierri I, Levis A. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007, 25:3746-3752. 10.1200/JCO.2007.11.6525, 17646666.
5. GNU Project, The Comprhensive R Archive Network. R 2.5.1. Institute for Statistics and Mathematics of the WU Wien., http://cran.r-project.org/
6. Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P, Fillet G. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999, 94:429-433.
7. Jerusalem G, Warland V, Najjar F, Paulus P, Fassotte MF, Fillet G, Rigo P. Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma. Nucl Med Commun 1999, 20:13-20. 10.1097/00006231-199901000-00004, 9949408.
8. Stumpe KD, Urbinelli M, Steinert HC, Glanzmann C, Buck A, von Schulthess GK. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Eur J Nucl Med 1998, 25:721-728. 10.1007/s002590050275, 9662594.
9. Kostakoglu L, Goldsmith SJ. Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and follow-up of lymphoma: is it time to shift gears?. Eur J Nucl Med 2000, 27:1564-1578. 10.1007/s002590000340, 11083548.
10. O'Doherty MJ, Macdonald EA, Barrington SF, Mikhaeel NG, Schey S. Positron emission tomography in the management of lymphomas. Clin Oncol (R Coll Radiol) 2002, 14:415-426.
11. Schiepers C, Filmont JE, Czernin J. PET for staging of Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2003, 30(Suppl 1):S82-88.
12. Naumann R, Beuthien-Baumann B, Reiss A, Schulze J, Hänel A, Bredow J, Kühnel G, Kropp J, Hänel M, Laniado M, Kotzerke J, Ehninger G. Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma. Br J Cancer 2004, 90:620-625. 10.1038/sj.bjc.6601561, 2409608, 14760374.
13. Cheson BD. The International Harmonization Project for response criteria in lymphoma clinical trials. Hematol Oncol Clin North Am 2007, 21:841-54. 10.1016/j.hoc.2007.06.011, 17908623.
14. Advani R, Maeda L, Lavori P, Quon A, Hoppe R, Breslin S, Rosenberg SA, Horning SJ. Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease. J Clin Oncol 2007, 25:3902-3907. 10.1200/JCO.2007.11.9867, 17664458.
15. Grow AQE, Loo BW. Metabolic tumor volume as an independent prognostic factor in lymphoma [Abstract 6594]. Journal of Clinical Oncology 2005, 23:583S.
16. Horning SJ, Hoppe RT, Breslin S, Bartlett NL, Brown BW, Rosenberg SA. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol 2002, 20:630-637. 10.1200/JCO.20.3.630, 11821442.
17. Donaldson SS, Hudson MM, Lamborn KR, Link MP, Kun L, Billett AL, Marcus KC, Hurwitz CA, Young JA, Tarbell NJ, Weinstein HJ. VAMP and low-dose, involved-field radiation for children and adolescents with favorable, early-stage Hodgkin's disease: results of a prospective clinical trial. J Clin Oncol 2002, 20:3081-3087. 10.1200/JCO.2002.12.101, 12118021.
18. Diehl V, Franklin J, Hasenclever D, Tesch H, Pfreundschuh M, Lathan B, Paulus U, Sieber M, Rüffer JU, Sextro M, Engert A, Wolf J, Hermann R, Holmer L, Stappert-Jahn U, Winnerlein-Trump E, Wulf G, Krause S, Glunz A, von Kalle K, Bischoff H, Haedicke C, Dühmke E, Georgii A, Loeffler M. BEACOPP: a new regimen for advanced Hodgkin's disease. German Hodgkin's Lymphoma Study Group. Ann Oncol 1998, 9(Suppl 5):S67-71.
19. Lee PWD, Lavori P, Quon A, Hara W, Maxim P, Le QT, Wakelee H, Donington J, Graves E, Loo BW. Metabolic tumor burden predicts for disease progression and death in lung cancer. Int J Radiation Oncology Biol Phys 2007, 69:328-333.
20. GraphPad Kaplan-Meier Analysis. GraphPad Prism version 4.0a for Macintosh ed 2003, San Diego, California, GraphPad.
21. Advani RH, Hoppe RT, Maeda LS, Baer DM, Mason J, Rosenberg SA, Horning SJ. Stage I-IIA Non-bulky Hodgkin's Lymphoma. Is Further Distinction Based on Prognostic Factors Useful? The Stanford Experience. Int J Radiat Oncol Biol Phys 2010,